StockData
Xenetic Biosciences, Inc. logo

Xenetic Biosciences, Inc. (XBIO) stock

XBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/3064% below fair value
$1.61+0.12 (+8.05%)

Close on Nov 17, 2026Market cap $3.77MP/E –Yield –

Xenetic Biosciences price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Xenetic Biosciences's price to sales ratio was 1.3× on Nov 11, 2026, against 1.4× a year earlier. Over the last 5 years it ranged from 1.2× to 17.6×, with a median of 2.6×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20261.3×+0.2
2025Dec 31, 20251.2×−1.3
2024Dec 31, 20242.4×−0.7
2023Dec 29, 20233.1×+0.4
2022Dec 30, 20222.7×−14.9
2021Dec 31, 202117.6×−24.8
2020Dec 31, 202042.4×+40.4
2018Apr 30, 20182.1×−5.1
2017Apr 28, 20177.2×–

More Xenetic Biosciences figures

See a number that looks wrong?